Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.

ABSTRACT:

Background

Tumor ablation is often employed for unresectable colorectal liver metastases. However, no survival benefit has ever been demonstrated in prospective randomized studies. Here, we investigate the long-term benefits of such an aggressive approach.

Methods

In this randomized phase II trial, 119 patients with unresectable colorectal liver metastases (n < 10 and no extrahepatic disease) received systemic treatment alone or systemic treatment plus aggressive local treatment by radiofrequency ablation ± resection. Previously, we reported that the primary end point (30-month overall survival [OS] > 38%) was met. We now report on long-term OS results. All statistical tests were two-sided. The analyses were according to intention to treat.

Results

At a median follow

SUBMITTER: Ruers T 

PROVIDER: S-EPMC5408999 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature